Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. Lancet Oncol. We explore here the role of REGO as maintenance therapy after 1 st line treatment.
There was no planned cross-over. Median follow-up was 27 mo. Median duration of treatment was 3. The primary objective was assessable in pts events. According to investigator assessment, median PFS was 3. Median OS was This was associated with a non-significant trend of OS improvement.
This benefit must be balanced with the occurrence of AEs. This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. Abstract O. Clinical trial identification NCT May 15, Editorial acknowledgement Legal entity responsible for the study Centre Oscar Lambret. Funding Has not received any funding.
Disclosure All authors have declared no conflicts of interest. Resources from the same session. Resources: Abstract Slides Webcast. Resources: Slides Webcast. Resources: Webcast. Customise settings Reject all cookies Accept all cookies. Necessary cookies Necessary cookies enable core functionality. Save selected settings.
